{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T13:35:04Z","timestamp":1790602504377,"version":"4.1.0"},"reference-count":144,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2024,5,5]],"date-time":"2024-05-05T00:00:00Z","timestamp":1714867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Diabetes mellitus (DM) is known as the first non-communicable global epidemic. It is estimated that 537 million people have DM, but the condition has been properly diagnosed in less than half of these patients. Despite numerous preventive measures, the number of DM cases is steadily increasing. The state of chronic hyperglycaemia in the body leads to numerous complications, including diabetic cardiomyopathy (DCM). A number of pathophysiological mechanisms are behind the development and progression of cardiomyopathy, including increased oxidative stress, chronic inflammation, increased synthesis of advanced glycation products and overexpression of the biosynthetic pathway of certain compounds, such as hexosamine. There is extensive research on the treatment of DCM, and there are a number of therapies that can stop the development of this complication. Among the compounds used to treat DCM are antiglycaemic drugs, hypoglycaemic drugs and drugs used to treat myocardial failure. An important element in combating DCM that should be kept in mind is a healthy lifestyle\u2014a well-balanced diet and physical activity. There is also a group of compounds\u2014including coenzyme Q10, antioxidants and modulators of signalling pathways and inflammatory processes, among others\u2014that are being researched continuously, and their introduction into routine therapies is likely to result in greater control and more effective treatment of DM in the future. This paper summarises the latest recommendations for lifestyle and pharmacological treatment of cardiomyopathy in patients with DM.<\/jats:p>","DOI":"10.3390\/ijms25095027","type":"journal-article","created":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T15:05:01Z","timestamp":1715007901000},"page":"5027","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Pathophysiology and Advances in the Therapy of Cardiomyopathy in Patients with Diabetes Mellitus"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-8963-6882","authenticated-orcid":false,"given":"Patryk","family":"Graczyk","sequence":"first","affiliation":[{"name":"Department of Physiology, Pomeranian Medical University, 70-111 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8798-5415","authenticated-orcid":false,"given":"Aleksandra","family":"Dach","sequence":"additional","affiliation":[{"name":"Department of Physiology, Pomeranian Medical University, 70-111 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0384-1692","authenticated-orcid":false,"given":"Kamil","family":"Dyrka","sequence":"additional","affiliation":[{"name":"Department of Pediatric Endocrinology and Rheumatology, Institute of Pediatrics, Poznan University of Medical Sciences, 60-572 Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6557-1208","authenticated-orcid":false,"given":"Andrzej","family":"Pawlik","sequence":"additional","affiliation":[{"name":"Department of Physiology, Pomeranian Medical University, 70-111 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/0002-9149(72)90595-4","article-title":"New type of cardiomyopathy associated with diabetic glomerulosclerosis","volume":"30","author":"Rubler","year":"1972","journal-title":"Am. J. Cardiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1172\/JCI108843","article-title":"Evidence for cardiomyopathy in familial diabetes mellitus","volume":"60","author":"Regan","year":"1977","journal-title":"J. Clin. Investig."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1001\/jama.1979.03290450033020","article-title":"Diabetes and cardiovascular disease. The Framingham study","volume":"241","author":"Kannel","year":"1979","journal-title":"JAMA"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/HJH.0b013e3283331169","article-title":"Diabetes and incident heart failure in hypertensive and normotensive participants of the Strong Heart Study","volume":"28","author":"Devereux","year":"2010","journal-title":"J. Hypertens."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1161\/01.CIR.101.19.2271","article-title":"Impact of diabetes on cardiac structure and function: The strong heart study","volume":"101","author":"Devereux","year":"2000","journal-title":"Circulation"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"109119","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1001\/jama.1988.03410230074031","article-title":"The impact of diabetes on survival following myocardial infarction in men vs women. The Framingham Study","volume":"260","author":"Abbott","year":"1988","journal-title":"JAMA"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCRESAHA.117.311586","article-title":"Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity","volume":"122","author":"Jia","year":"2018","journal-title":"Circ. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12933-017-0582-y","article-title":"Admission blood glucose and 10-year mortality among patients with or without pre-existing diabetes mellitus hospitalized with heart failure","volume":"16","author":"Kornowski","year":"2017","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","article-title":"Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study","volume":"321","author":"Stratton","year":"2000","journal-title":"BMJ"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.hfc.2019.02.003","article-title":"Diabetic Cardiomyopathy: Definition, Diagnosis, and Therapeutic Implications","volume":"15","author":"Paolillo","year":"2019","journal-title":"Heart Fail. Clin."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.pcad.2019.03.003","article-title":"Diabetic cardiomyopathy\u2014A comprehensive updated review","volume":"62","author":"Murtaza","year":"2019","journal-title":"Prog. Cardiovasc. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1032268","DOI":"10.3389\/fendo.2022.1032268","article-title":"Diabetic cardiomyopathy: Clinical phenotype and practice","volume":"13","author":"Zhao","year":"2022","journal-title":"Front. Endocrinol."},{"key":"ref_14","first-page":"e876","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S0140-6736(18)31808-7","article-title":"Heart failure drug treatment","volume":"393","author":"Rossignol","year":"2019","journal-title":"Lancet"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Nakamura, K., Miyoshi, T., Yoshida, M., Akagi, S., Saito, Y., Ejiri, K., Matsuo, N., Ichikawa, K., Iwasaki, K., and Naito, T. (2022). Pathophysiology and Treatment of Diabetic Cardiomyopathy and Heart Failure in Patients with Diabetes Mellitus. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23073587"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1016\/j.amjmed.2017.04.010","article-title":"Diabetes Mellitus and Heart Failure","volume":"130","author":"Lehrke","year":"2017","journal-title":"Am. J. Med."},{"key":"ref_18","first-page":"e28","article-title":"Heart disease and stroke statistics\u20142014 update: A report from the American Heart Association","volume":"129","author":"Go","year":"2014","journal-title":"Circulation"},{"key":"ref_19","first-page":"379","article-title":"Cardiomyocyte defects in diabetic models and protection with cardiac-targeted transgenes","volume":"112","author":"Shen","year":"2005","journal-title":"Methods Mol. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1172\/JCI24405","article-title":"Mitochondrial energy metabolism in heart failure: A question of balance","volume":"115","author":"Huss","year":"2005","journal-title":"J. Clin. Investig."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1161\/01.RES.62.3.535","article-title":"Changes in substrate metabolism and effects of excess fatty acids in reperfused myocardium","volume":"62","author":"Liedtke","year":"1988","journal-title":"Circ. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1161\/CIRCRESAHA.120.315913","article-title":"Basic Mechanisms of Diabetic Heart Disease","volume":"126","author":"Ritchie","year":"2020","journal-title":"Circ. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1146\/annurev.med.53.082901.104057","article-title":"Lipotoxic diseases","volume":"53","author":"Unger","year":"2002","journal-title":"Annu. Rev. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"750382","DOI":"10.3389\/fcell.2021.750382","article-title":"Mitophagy in Diabetic Cardiomyopathy: Roles and Mechanisms","volume":"9","author":"Zheng","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"E268","DOI":"10.1152\/ajpendo.00314.2018","article-title":"Mitochondrial dysfunction in type 2 diabetes mellitus: An organ-based analysis","volume":"316","author":"Pinti","year":"2019","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"154910","DOI":"10.1016\/j.metabol.2021.154910","article-title":"Heart failure in diabetes","volume":"125","author":"Jankauskas","year":"2021","journal-title":"Metabolism"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.1161\/01.CIR.0000072789.89096.10","article-title":"Abnormal cardiac and skeletal muscle energy metabolism in patients with type 2 diabetes","volume":"107","author":"Madsen","year":"2003","journal-title":"Circulation"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"141","DOI":"10.4239\/wjd.v1.i5.141","article-title":"Role of the renin angiotensin system in diabetic nephropathy","volume":"1","author":"Chawla","year":"2010","journal-title":"World J. Diabetes"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Batista, J.P.T., Faria, A.O.V., Ribeiro, T.F.S., and Sim\u00f5es E Silva, A.C. (2023). The Role of Renin-Angiotensin System in Diabetic Cardiomyopathy: A Narrative Review. Life, 13.","DOI":"10.3390\/life13071598"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1161\/CIRCRESAHA.110.223545","article-title":"Oxidative stress and diabetic complications","volume":"107","author":"Giacco","year":"2010","journal-title":"Circ. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"166170","DOI":"10.1016\/j.bbadis.2021.166170","article-title":"VCAM-1 as a predictor biomarker in cardiovascular disease","volume":"1867","author":"Troncoso","year":"2021","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1161\/CIRCRESAHA.111.243972","article-title":"Biochemistry, physiology, and pathophysiology of NADPH oxidases in the cardiovascular system","volume":"110","author":"Griendling","year":"2012","journal-title":"Circ. Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"5913374","DOI":"10.1155\/2022\/5913374","article-title":"Oxidative Stress Signaling Mediated Pathogenesis of Diabetic Cardiomyopathy","volume":"2022","author":"Tang","year":"2022","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"44230","DOI":"10.1074\/jbc.M303810200","article-title":"Diabetes and the accompanying hyperglycemia impairs cardiomyocyte calcium cycling through increased nuclear O-GlcNAcylation","volume":"278","author":"Clark","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.2337\/dc23-S006","article-title":"6. Glycemic Targets: Standards of Care in Diabetes\u20142023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"key":"ref_36","first-page":"H1775","article-title":"Cardiac responses to acute insulin-induced hypoglycemia in humans","volume":"258","author":"Fisher","year":"1990","journal-title":"Am. J. Physiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.metabol.2012.12.003","article-title":"Reduced capacity of heart rate regulation in response to mild hypoglycemia induced by glibenclamide and physical exercise in type 2 diabetes","volume":"62","author":"Soydan","year":"2013","journal-title":"Metabolism"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/j.1464-5491.1992.tb01834.x","article-title":"Hypoglycaemia and cardiac arrhythmias in patients with type 2 diabetes mellitus","volume":"9","author":"Jorfeldt","year":"1992","journal-title":"Diabet Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"S132","DOI":"10.2337\/dc11-s220","article-title":"Hypoglycemia and cardiovascular risks","volume":"34","author":"Frier","year":"2011","journal-title":"Diabetes Care"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Christou, M.A., Christou, P.A., Kyriakopoulos, C., Christou, G.A., and Tigas, S. (2023). Effects of Hypoglycemia on Cardiovascular Function in Patients with Diabetes. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24119357"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.pharmthera.2016.11.013","article-title":"Cardiac oxidative stress in diabetes: Mechanisms and therapeutic potential","volume":"172","author":"Faria","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"166044","DOI":"10.1016\/j.bbadis.2020.166044","article-title":"Diabetic fibrosis","volume":"1867","author":"Tuleta","year":"2021","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e104771","DOI":"10.1371\/journal.pone.0104771","article-title":"NLRP3 gene silencing ameliorates diabetic cardiomyopathy in a type 2 diabetes rat model","volume":"9","author":"Luo","year":"2014","journal-title":"PLoS ONE"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"865489","DOI":"10.3389\/fnut.2022.865489","article-title":"Low Carbohydrate Diets for Diabetic Cardiomyopathy: A Hypothesis","volume":"9","author":"Rasmussen","year":"2022","journal-title":"Front. Nutr."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e472","DOI":"10.1161\/CIR.0000000000001031","article-title":"2021 Dietary Guidance to Improve Cardiovascular Health: A Scientific Statement From the American Heart Association","volume":"144","author":"Lichtenstein","year":"2021","journal-title":"Circulation"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.amjmed.2020.12.017","article-title":"Fish Consumption and Cardiovascular Health: A Systematic Review","volume":"134","author":"Krittanawong","year":"2021","journal-title":"Am. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2337\/ds19-0073","article-title":"An Update on the Mediterranean, Vegetarian, and DASH Eating Patterns in People with Type 2 Diabetes","volume":"33","author":"Benson","year":"2020","journal-title":"Diabetes Spectr."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"177","DOI":"10.4239\/wjd.v4.i5.177","article-title":"Diabetic cardiomyopathy: Pathophysiology, diagnostic evaluation and management","volume":"4","author":"Pappachan","year":"2013","journal-title":"World J. Diabetes"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"729","DOI":"10.3389\/fendo.2018.00729","article-title":"Physical Exercise and Its Protective Effects on Diabetic Cardiomyopathy: What Is the Evidence?","volume":"9","author":"Zheng","year":"2018","journal-title":"Front. Endocrinol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Tamura, Y., Omura, T., Toyoshima, K., and Araki, A. (2020). Nutrition Management in Older Adults with Diabetes: A Review on the Importance of Shifting Prevention Strategies from Metabolic Syndrome to Frailty. Nutrients, 12.","DOI":"10.3390\/nu12113367"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Petroni, M.L., Brodosi, L., Marchignoli, F., Sasdelli, A.S., Caraceni, P., Marchesini, G., and Ravaioli, F. (2021). Nutrition in Patients with Type 2 Diabetes: Present Knowledge and Remaining Challenges. Nutrients, 13.","DOI":"10.3390\/nu13082748"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"American Diabetes Association (2022). Standards of Medical Care in Diabetes\u20142022 Abridged for Primary Care Providers. Clin. Diabetes, 40, 10\u201338.","DOI":"10.2337\/cd22-as01"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"American Diabetes Association (2021). 8. Obesity Management for the Treatment of Type 2 Diabetes: Standards of Medical Care in Diabetes\u20142021. Diabetes Care, 44, S100\u2013S110.","DOI":"10.2337\/dc21-S008"},{"key":"ref_54","first-page":"CD006763","article-title":"Altered dietary salt intake for preventing diabetic kidney disease and its progression","volume":"1","author":"Hodson","year":"2023","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S1357-2725(02)00271-6","article-title":"Inflammation and angiotensin II","volume":"35","author":"Suzuki","year":"2003","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e009890","DOI":"10.1161\/JAHA.118.009890","article-title":"Renin-Angiotensin-Aldosterone System, Glucose Metabolism and Incident Type 2 Diabetes Mellitus: MESA","volume":"7","author":"Joseph","year":"2018","journal-title":"J. Am. Heart Assoc."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S0140-6736(00)02212-1","article-title":"Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: A systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group","volume":"355","author":"Flather","year":"2000","journal-title":"Lancet"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/cvr\/cvy226","article-title":"Telmisartan and thiorphan combination treatment attenuates fibrosis and apoptosis in preventing diabetic cardiomyopathy","volume":"115","author":"Malek","year":"2019","journal-title":"Cardiovasc. Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1177\/1535370219861283","article-title":"LCZ696, an angiotensin receptor-neprilysin inhibitor, ameliorates diabetic cardiomyopathy by inhibiting inflammation, oxidative stress and apoptosis","volume":"244","author":"Ge","year":"2019","journal-title":"Exp. Biol. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1161\/01.CIR.101.2.122","article-title":"Carvedilol inhibits reactive oxygen species generation by leukocytes and oxidative damage to amino acids","volume":"101","author":"Dandona","year":"2000","journal-title":"Circulation"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0033-0620(98)80030-3","article-title":"Beta-adrenergic blockade in chronic heart failure: Principles, progress, and practice","volume":"41","author":"Packer","year":"1998","journal-title":"Prog. Cardiovasc. Dis."},{"key":"ref_62","first-page":"647","article-title":"Nebivolol in the treatment of chronic heart failure","volume":"3","author":"Veverka","year":"2007","journal-title":"Vasc. Health Risk Manag."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1161\/01.CIR.0000035653.72855.BF","article-title":"Effect of carvedilol on the morbidity of patients with severe chronic heart failure: Results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"9556","DOI":"10.1038\/s41598-018-27799-y","article-title":"Beta-blocker use and cardiovascular event risk in patients with heart failure with preserved ejection fraction","volume":"8","author":"Tsujimoto","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/1475-2840-12-172","article-title":"Eplerenone attenuated cardiac steatosis, apoptosis and diastolic dysfunction in experimental type-II diabetes","volume":"12","author":"Picatoste","year":"2013","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"9232065","DOI":"10.1155\/2018\/9232065","article-title":"Spironolactone Protects against Diabetic Cardiomyopathy in Streptozotocin-Induced Diabetic Rats","volume":"2018","author":"Liu","year":"2018","journal-title":"J. Diabetes Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13098-023-01064-3","article-title":"Finerenone attenuates myocardial apoptosis, metabolic disturbance and myocardial fibrosis in type 2 diabetes mellitus","volume":"15","author":"Jin","year":"2023","journal-title":"Diabetol. Metab. Syndr."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"448","DOI":"10.3389\/fendo.2020.00448","article-title":"Heart Failure with Type 2 Diabetes Mellitus: Association Between Antihyperglycemic Agents, Glycemic Control, and Ejection Fraction","volume":"11","author":"Lin","year":"2020","journal-title":"Front. Endocrinol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1146\/annurev-med-051013-110046","article-title":"The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus","volume":"66","author":"Vallon","year":"2015","journal-title":"Annu. Rev. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/dom.12572","article-title":"Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes","volume":"17","author":"Chilton","year":"2015","journal-title":"Diabetes Obes. Metab."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"9927533","DOI":"10.1155\/2021\/9927533","article-title":"The Role of SGLT2 Inhibitors in Heart Failure: A Systematic Review and Meta-Analysis","volume":"2021","author":"Tsampasian","year":"2021","journal-title":"Cardiol. Res. Pract."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.2337\/dc15-1380","article-title":"Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern with SGLT2 Inhibitors","volume":"38","author":"Rosenstock","year":"2015","journal-title":"Diabetes Care"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.2337\/db15-1356","article-title":"Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects without Diabetes and Patients with Type 2 Diabetes","volume":"65","author":"Ferrannini","year":"2016","journal-title":"Diabetes"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1161\/CIRCULATIONAHA.118.036459","article-title":"Cardiovascular Effects of Treatment with the Ketone Body 3-Hydroxybutyrate in Chronic Heart Failure Patients","volume":"139","author":"Nielsen","year":"2019","journal-title":"Circulation"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"7677","DOI":"10.1038\/s41598-017-08055-1","article-title":"Beta-hydroxybutyrate, an endogenic NLRP3 inflammasome inhibitor, attenuates stress-induced behavioral and inflammatory responses","volume":"7","author":"Yamanashi","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1126\/science.1227166","article-title":"Suppression of oxidative stress by \u03b2-hydroxybutyrate, an endogenous histone deacetylase inhibitor","volume":"339","author":"Shimazu","year":"2013","journal-title":"Science"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12933-019-0816-2","article-title":"SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart","volume":"18","author":"Li","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12933-019-0980-4","article-title":"Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy","volume":"19","author":"Arow","year":"2020","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1210\/endo.134.5.8156917","article-title":"Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide-1 in the mouse","volume":"134","author":"Campos","year":"1994","journal-title":"Endocrinology"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"86","DOI":"10.2337\/diabetes.48.1.86","article-title":"Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: Studies with the antagonist exendin 9\u201339","volume":"48","author":"Edwards","year":"1999","journal-title":"Diabetes"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1007\/s10557-020-07006-9","article-title":"Exendin-4 Attenuates Remodeling in the Remote Myocardium of Rats after an Acute Myocardial Infarction by Activating \u03b2-Arrestin-2, Protein Phosphatase 2A, and Glycogen Synthase Kinase-3 and Inhibiting \u03b2-Catenin","volume":"35","author":"Eid","year":"2021","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1111\/1440-1681.13299","article-title":"Exendin-4 protects the hearts of rats from ischaemia\/reperfusion injury by boosting antioxidant levels and inhibition of JNK\/p","volume":"47","author":"Eid","year":"2020","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1161\/atv.0000615456.97862.30","article-title":"Endothelial GLP-1 (Glucagon-Like Peptide-1) Receptor Mediates Cardiovascular Protection by Liraglutide In Mice with Experimental Arterial Hypertension","volume":"40","author":"Frenis","year":"2020","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.7150\/ijbs.59965","article-title":"GLP-1 receptor agonists (GLP-1RAs): Cardiovascular actions and therapeutic potential","volume":"17","author":"Ma","year":"2021","journal-title":"Int. J. Biol. Sci."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.clinthera.2022.12.006","article-title":"Effect of Glucagon-like Peptide-1 Receptor Agonists on Prognosis of Heart Failure and Cardiac Function: A Systematic Review and Meta-analysis of Randomized Controlled Trials","volume":"45","author":"Huixing","year":"2023","journal-title":"Clin. Ther."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.cardfail.2023.03.017","article-title":"Increased Risk of Heart Failure Hospitalization with GLP-1 Receptor Agonists in Patients with Reduced Ejection Fraction: A Meta-Analysis of the EXSCEL and FIGHT Trials","volume":"29","author":"Neves","year":"2023","journal-title":"J. Card. Fail."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"102427","DOI":"10.1016\/j.dsx.2022.102427","article-title":"Adverse drug reactions of GLP-1 agonists: A systematic review of case reports","volume":"16","author":"Shetty","year":"2022","journal-title":"Diabetes Metab. Syndr."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12933-016-0490-6","article-title":"Differential effects of glucagon-like peptide-1 receptor agonists on heart rate","volume":"16","author":"Lorenz","year":"2017","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/s41574-020-0399-8","article-title":"Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus","volume":"16","author":"Deacon","year":"2020","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee (2021). 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes\u20142022. Diabetes Care, 45, S144\u2013S174.","DOI":"10.2337\/dc22-S010"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1161\/CIRCULATIONAHA.114.010389","article-title":"Heart failure, saxagliptin, and diabetes mellitus: Observations from the SAVOR-TIMI 53 randomized trial","volume":"130","author":"Scirica","year":"2014","journal-title":"Circulation"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.cardfail.2012.07.009","article-title":"Dipeptidyl peptidase 4 inhibition increases myocardial glucose uptake in nonischemic cardiomyopathy","volume":"18","author":"Witteles","year":"2012","journal-title":"J. Card. Fail."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/s12276-023-00958-6","article-title":"Evogliptin, a DPP-4 inhibitor, prevents diabetic cardiomyopathy by alleviating cardiac lipotoxicity in db\/db mice","volume":"55","author":"Pham","year":"2023","journal-title":"Exp. Mol. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"585","DOI":"10.4330\/wjc.v13.i10.585","article-title":"Cardiovascular efficacy and safety of dipeptidyl peptidase-4 inhibitors: A meta-analysis of cardiovascular outcome trials","volume":"13","author":"Patoulias","year":"2021","journal-title":"World J. Cardiol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.ihj.2020.07.009","article-title":"Modern sulphonylureas and cardiovascular adverse effects: Will CAROLINA put an end to the controversy?","volume":"72","author":"John","year":"2020","journal-title":"Indian Heart J."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee (2021). 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes\u20142022. Diabetes Care, 45, S125\u2013S143.","DOI":"10.2337\/dc22-S009"},{"key":"ref_98","unstructured":"Holland, I.B., Cole, S.P.C., Kuchler, K., and Higgins, C.F. (2003). ABC Proteins, Academic Press."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.yjmcc.2004.11.024","article-title":"Function and distribution of the SUR isoforms and splice variants","volume":"39","author":"Shi","year":"2005","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1161\/01.CIR.74.5.1124","article-title":"Preconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium","volume":"74","author":"Murry","year":"1986","journal-title":"Circulation"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"S368","DOI":"10.2337\/diabetes.51.2007.S368","article-title":"Sulfonylurea stimulation of insulin secretion","volume":"51","author":"Proks","year":"2002","journal-title":"Diabetes"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1161\/CIRCRESAHA.107.165324","article-title":"The sulfonylurea receptor, an atypical ATP-binding cassette protein, and its regulation of the KATP channel","volume":"102","author":"Burke","year":"2008","journal-title":"Circ. Res."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"UK Prospective Diabetes Study (UKPDS) Group (1998). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 352, 837\u2013853.","DOI":"10.1016\/S0140-6736(98)07019-6"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jchf.2021.11.001","article-title":"Clinical Outcomes with Metformin and Sulfonylurea Therapies Among Patients with Heart Failure and Diabetes","volume":"10","author":"Khan","year":"2022","journal-title":"JACC Heart Fail."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1001\/jama.2019.13772","article-title":"Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients with Type 2 Diabetes: The CAROLINA Randomized Clinical Trial","volume":"322","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"44","DOI":"10.4103\/picr.PICR_157_19","article-title":"CARdiovascular Outcome study of LINAgliptin versus glimepiride in patients with T2D trial","volume":"11","author":"Nath","year":"2020","journal-title":"Perspect. Clin. Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.2337\/dci22-0014","article-title":"Heart Failure: An Underappreciated Complication of Diabetes. A Consensus Report of the American Diabetes Association","volume":"45","author":"Januzzi","year":"2022","journal-title":"Diabetes Care"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2337\/dc13-2112","article-title":"The diabetes control and complications trial\/epidemiology of diabetes interventions and complications study at 30 years: Overview","volume":"37","author":"Nathan","year":"2014","journal-title":"Diabetes Care"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1002\/ejhf.1535","article-title":"Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction","volume":"21","author":"Shen","year":"2019","journal-title":"Eur. J. Heart Fail."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"e186125","DOI":"10.1001\/jamanetworkopen.2018.6125","article-title":"Association of Second-line Antidiabetic Medications with Cardiovascular Events among Insured Adults with Type 2 Diabetes","volume":"1","author":"Karam","year":"2018","journal-title":"JAMA Netw. Open"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"e002708","DOI":"10.1136\/bmjdrc-2021-002708","article-title":"Insulin treatment in patients with diabetes mellitus and heart failure in the era of new antidiabetic medications","volume":"10","author":"Staszewsky","year":"2022","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s11892-019-1270-y","article-title":"Thiazolidinediones: The Forgotten Diabetes Medications","volume":"19","author":"Lebovitz","year":"2019","journal-title":"Curr. Diabetes Rep."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"11513","DOI":"10.1073\/pnas.96.20.11513","article-title":"Troglitazone prevents mitochondrial alterations, beta cell destruction, and diabetes in obese prediabetic rats","volume":"96","author":"Higa","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1345\/aph.1K666","article-title":"Thiazolidinediones in type 2 diabetes: A cardiology perspective","volume":"42","author":"Khanderia","year":"2008","journal-title":"Ann. Pharmacother."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1161\/01.CIR.0000103683.99399.7E","article-title":"Thiazolidinedione use, fluid retention, and congestive heart failure: A consensus statement from the American Heart Association and American Diabetes Association","volume":"108","author":"Nesto","year":"2003","journal-title":"Circulation"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2146\/ajhp060446","article-title":"Thiazolidinediones in patients with type 2 diabetes mellitus and heart failure","volume":"64","author":"Granberry","year":"2007","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1161\/CIRCRESAHA.108.190918","article-title":"Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure","volume":"104","author":"Gundewar","year":"2009","journal-title":"Circ. Res."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1161\/CIRCULATIONAHA.108.798561","article-title":"Metformin prevents progression of heart failure in dogs: Role of AMP-activated protein kinase","volume":"119","author":"Sasaki","year":"2009","journal-title":"Circulation"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.2337\/db10-0351","article-title":"Improvement of cardiac functions by chronic metformin treatment is associated with enhanced cardiac autophagy in diabetic OVE26 mice","volume":"60","author":"Xie","year":"2011","journal-title":"Diabetes"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/1753-0407.12900","article-title":"Associations between metformin use and vitamin B(12) levels, anemia, and neuropathy in patients with diabetes: A meta-analysis","volume":"11","author":"Yang","year":"2019","journal-title":"J. Diabetes"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s12016-020-08791-9","article-title":"Anti-inflammatory Action of Statins in Cardiovascular Disease: The Role of Inflammasome and Toll-like Receptor Pathways","volume":"60","author":"Koushki","year":"2021","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Liberale, L., Carbone, F., Camici, G.G., and Montecucco, F. (2019). IL-1\u03b2 and Statin Treatment in Patients with Myocardial Infarction and Diabetic Cardiomyopathy. J. Clin. Med., 8.","DOI":"10.3390\/jcm8111764"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1161\/01.CIR.98.19.2088","article-title":"Mechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism","volume":"98","author":"Staels","year":"1998","journal-title":"Circulation"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1475-2840-8-16","article-title":"Diabetic cardiomyopathy: Effects of fenofibrate and metformin in an experimental model\u2014The Zucker diabetic rat","volume":"8","author":"Forcheron","year":"2009","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1007\/s00125-012-2495-3","article-title":"Coenzyme Q10 attenuates diastolic dysfunction, cardiomyocyte hypertrophy and cardiac fibrosis in the db\/db mouse model of type 2 diabetes","volume":"55","author":"Huynh","year":"2012","journal-title":"Diabetologia"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"e0296775","DOI":"10.1371\/journal.pone.0296775","article-title":"Ameliorating impact of coenzyme Q10 on the profile of adipokines, cardiomyopathy, and hematological markers correlated with the glucotoxicity sequelae in diabetic rats","volume":"19","author":"Jbrael","year":"2024","journal-title":"PLoS ONE"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.atherosclerosis.2005.02.024","article-title":"Development of atherosclerosis in the diabetic BALB\/c mice. Prevention with Vitamin E administration","volume":"182","author":"Otero","year":"2005","journal-title":"Atherosclerosis"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.cardfail.2007.07.002","article-title":"Dietary supplementation with vitamin E ameliorates cardiac failure in type I diabetic cardiomyopathy by suppressing myocardial generation of 8-iso-prostaglandin F2alpha and oxidized glutathione","volume":"13","author":"Hamblin","year":"2007","journal-title":"J. Card. Fail."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0167-5273(93)90149-B","article-title":"Effect of zinc deficiency on lipid peroxidation status and infarct size in rat hearts","volume":"41","author":"Coudray","year":"1993","journal-title":"Int. J. Cardiol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s00210-013-0904-x","article-title":"Tempol ameliorates cardiac fibrosis in streptozotocin-induced diabetic rats: Role of oxidative stress in diabetic cardiomyopathy","volume":"386","author":"Taye","year":"2013","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"ref_131","first-page":"42","article-title":"Tempol a superoxide dismutase mimic reduces cardiac muscle cell death through the control of oxidative stress in streptozotocin-induced diabetes","volume":"11","author":"Tichati","year":"2024","journal-title":"Egypt. J. Basic Appl. Sci."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"175342","DOI":"10.1016\/j.ejphar.2022.175342","article-title":"Resveratrol improves diabetic cardiomyopathy by preventing asymmetric dimethylarginine-caused peroxisome proliferator-activated receptor-\u03b3 coactivator-1\u03b1 acetylation","volume":"936","author":"Fang","year":"2022","journal-title":"Eur. J. Pharmacol."},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Jubaidi, F.F., Zainalabidin, S., Taib, I.S., Hamid, Z.A., and Budin, S.B. (2021). The Potential Role of Flavonoids in Ameliorating Diabetic Cardiomyopathy via Alleviation of Cardiac Oxidative Stress, Inflammation and Apoptosis. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22105094"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1093\/cvr\/cvab123","article-title":"SERCA2a stimulation by istaroxime improves intracellular Ca2+ handling and diastolic dysfunction in a model of diabetic cardiomyopathy","volume":"118","author":"Torre","year":"2022","journal-title":"Cardiovasc. Res."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"115179","DOI":"10.1016\/j.bcp.2022.115179","article-title":"Alpha-lipoic acid treatment improves adverse cardiac remodelling in the diabetic heart\u2014The role of cardiac hydrogen sulfide-synthesizing enzymes","volume":"203","author":"Dugbartey","year":"2022","journal-title":"Biochem. Pharmacol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/1471-2261-14-150","article-title":"I(f) current channel inhibitor (ivabradine) deserves cardioprotective effect via down-regulating the expression of matrix metalloproteinase (MMP)-2 and attenuating apoptosis in diabetic mice","volume":"14","author":"Chen","year":"2014","journal-title":"BMC Cardiovasc. Disord."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.ihj.2016.04.023","article-title":"Metabolic manipulation in dilated cardiomyopathy: Assessing the role of trimetazidine","volume":"68","author":"Jatain","year":"2016","journal-title":"Indian Heart J."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"118306","DOI":"10.1016\/j.lfs.2020.118306","article-title":"Ranolazine protects against diabetic cardiomyopathy by activating the NOTCH1\/NRG1 pathway","volume":"261","author":"Chen","year":"2020","journal-title":"Life Sci."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"88","DOI":"10.4103\/HEARTVIEWS.HEARTVIEWS_18_18","article-title":"Ranolazine: Multifaceted Role beyond Coronary Artery Disease, a Recent Perspective","volume":"19","author":"Ghosh","year":"2018","journal-title":"Heart Views"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ygeno.2010.10.005","article-title":"Transcriptional regulation of mammalian miRNA genes","volume":"97","author":"Schanen","year":"2011","journal-title":"Genomics"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1016\/j.bbadis.2017.03.013","article-title":"Role of microRNA in diabetic cardiomyopathy: From mechanism to intervention","volume":"1863","author":"Guo","year":"2017","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.carpath.2012.07.004","article-title":"Emerging role of epigenetics and miRNA in diabetic cardiomyopathy","volume":"22","author":"Asrih","year":"2013","journal-title":"Cardiovasc. Pathol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3389\/fphys.2016.00125","article-title":"New Molecular Insights of Insulin in Diabetic Cardiomyopathy","volume":"7","author":"Westermeier","year":"2016","journal-title":"Front. Physiol."},{"key":"ref_144","first-page":"e43697","article-title":"Advances in the Management of Diabetes Mellitus: A Focus on Personalized Medicine","volume":"15","author":"Sugandh","year":"2023","journal-title":"Cureus"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/9\/5027\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:39:56Z","timestamp":1760107196000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/9\/5027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,5]]},"references-count":144,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["ijms25095027"],"URL":"https:\/\/doi.org\/10.3390\/ijms25095027","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,5]]}}}